J&J's Janssen scores partial victory in second Risperdal trial

NEW YORK, March 20 (Reuters) - A Philadelphia jury on Friday found that Johnson & Johnson's Janssen Pharmaceuticals failed to warn that antipsychotic drug Risperdal could cause male breast growth, in a case filed by a young man who had taken the drug, but it awarded no damages after finding no direct link to the man's condition.